Authorized purpose: Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.
Clinical role
Parallel worklist triage and notification prioritization for suspected ICH/LVO; cases remain in the standard-of-care reading workflow.
Images and patients
CT/CTA · Brain/head, including intracranial ICA and M1 for LVO and intracranial hemorrhage findings
Key limitation
Keep in mind: Not for mobile diagnostic use or primary diagnosis, and not a rule-out device. It does not replace angiography or full standard-of-care evaluation. The packet excludes or cautions against recent neurosurgery/endovascular intervention, recent stroke, symmetrical bilateral MCA occlusions, tumors or abscesses, coils, shunts, embolization, movement artifacts, and specified intracranial vascular pathologies; intended/validated scanners are Siemens, GE, and Philips.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain/head, including intracranial ICA and M1 for LVO and intracranial hemorrhage findings Input: DICOM non-contrast head CT from adults in the acute setting within 24 hours of symptom onset or last known well; the packet states intended/validated scanner manufacturers are Siemens, GE, and Philips.
Who uses it?Intended users: Medical imaging professionals and trained clinicians in hospital networks and healthcare facilities
What does the software produce?Output: Priority notifications for suspected ICH or LVO through the Brainomix 360 web interface or mobile application, with compressed informational previews; the original image is not altered and no specific location is marked.
What is its most important limitation?Key limitation: Not for mobile diagnostic use or primary diagnosis, and not a rule-out device. It does not replace angiography or full standard-of-care evaluation. The packet excludes or cautions against recent neurosurgery/endovascular intervention, recent stroke, symmetrical bilateral MCA occlusions, tumors or abscesses, coils, shunts, embolization, movement artifacts, and specified intracranial vascular pathologies; intended/validated scanners are Siemens, GE, and Philips.
Clinical takeaway. Clinical role: Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.
Evidence takeaway. Evidence from the reviewed source record: FDA reports three clinical studies. ICH standalone testing used 341 cases and found sensitivity 96.41% (95% CI 92.65%-98.65%) and specificity 96.55% (95% CI 92.94%-98.70%); the secondary SAH analysis reported sensitivity 85.71% and specificity 96.55%. A combined 267-case NCCT study reported LVO sensitivity 69.64% (CI 60.65%-77.70%) and specificity 89.57% (CI 82.92%-94.36%), with an ICH subset of sensitivity 95.00% and specificity 88.11%. A reader study reported all-reader LVO sensitivity 47.94% and a device-reader sensitivity difference of 20.52 percentage points.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.
DICOM non-contrast head CT from adults in the acute setting within 24 hours of symptom onset or last known well; the packet states intended/validated scanner manufacturers are Siemens, GE, and Philips.
Priority notifications for suspected ICH or LVO through the Brainomix 360 web interface or mobile application, with compressed informational previews; the original image is not altered and no specific location is marked.
Not for mobile diagnostic use or primary diagnosis, and not a rule-out device. It does not replace angiography or full standard-of-care evaluation. The packet excludes or cautions against recent neurosurgery/endovascular intervention, recent stroke, symmetrical bilateral MCA occlusions, tumors or abscesses, coils, shunts, embolization, movement artifacts, and specified intracranial vascular pathologies; intended/validated scanners are Siemens, GE, and Philips.
FDA reports three clinical studies. ICH standalone testing used 341 cases and found sensitivity 96.41% (95% CI 92.65%-98.65%) and specificity 96.55% (95% CI 92.94%-98.70%); the secondary SAH analysis reported sensitivity 85.71% and specificity 96.55%. A combined 267-case NCCT study reported LVO sensitivity 69.64% (CI 60.65%-77.70%) and specificity 89.57% (CI 82.92%-94.36%), with an ICH subset of sensitivity 95.00% and specificity 88.11%. A reader study reported all-reader LVO sensitivity 47.94% and a device-reader sensitivity difference of 20.52 percentage points.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA reports three clinical studies. ICH standalone testing used 341 cases and found sensitivity 96.41% (95% CI 92.65%-98.65%) and specificity 96.55% (95% CI 92.94%-98.70%); the secondary SAH analysis reported sensitivity 85.71% and specificity 96.55%. A combined 267-case NCCT study reported LVO sensitivity 69.64% (CI 60.65%-77.70%) and specificity 89.57% (CI 82.92%-94.36%), with an ICH subset of sensitivity 95.00% and specificity 88.11%. A reader study reported all-reader LVO sensitivity 47.94% and a device-reader sensitivity difference of 20.52 percentage points.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Brainomix 360 Triage Stroke regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K251983
Samplen=608
IndependenceIndependence not established
K251983
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K251983. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM non-contrast head CT from adults in the acute setting within 24 hours of symptom onset or last known well; the packet states intended/validated scanner manufacturers are Siemens, GE, and Philips.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Brainomix 360 Platform receives image data through preconfigured DICOM routing and runs on a physical or virtual server on premises or in the cloud. Notifications and non-diagnostic previews are available through a web user interface, mobile app, and diagnostic workstation workflow; the device does not remove cases from the reading queue.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Cloud-based and on-premises deployment are explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Deployment mode explicitly reported in the exact-submission ACR model card; hosting region and current commercial configuration still require vendor confirmation.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Priority notifications for suspected ICH or LVO through the Brainomix 360 web interface or mobile application, with compressed informational previews; the original image is not altered and no specific location is marked.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Priority notifications for suspected ICH or LVO through the Brainomix 360 web interface or mobile application, with compressed informational previews; the original image is not altered and no specific location is marked.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Cloud-based and on-premises deployment are explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-09-01
Deployment mode explicitly reported in the exact-submission ACR model card; hosting region and current commercial configuration still require vendor confirmation.
Brainomix 360 Platform receives image data through preconfigured DICOM routing and runs on a physical or virtual server on premises or in the cloud. Notifications and non-diagnostic previews are available through a web user interface, mobile app, and diagnostic workstation workflow; the device does not remove cases from the reading queue.
Brainomix's current official FAQ describes ISO 27001, GDPR, and DPA controls for the current Brainomix 360 family; this does not establish certificate scope, expiry, deployed configuration, or exact K243294 security controls.
Product family
Checked 2026-10-25
Obtain current certificate scope, data-processing terms, hosting region, encryption, identity/access, audit, retention, and incident-response evidence for the deployed release.
Cloud-based and on-premises deployment are explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.
ACR AI Central provides an exact-submission model card for Brainomix 360 Triage Stroke; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-19Last searched
26Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K251983 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.
Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.
Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.